New weekly shot aims to protect kidneys in obese patients
NCT ID NCT07134335
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a weekly injection called UBT251 in 180 overweight or obese adults with chronic kidney disease. The goal is to see if it can reduce protein in the urine (a sign of kidney damage) and help with weight control. Participants will receive either the drug or a placebo for 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- UBT251 injection (a weekly shot)
- What this could lead to
- If it works, this could point toward a treatment that slows kidney damage and helps with weight loss in people with chronic kidney disease.
- What could go wrong
- This is an early Phase II trial with only 180 people, so results may not apply to everyone. The drug may not improve kidney function or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk